Search results for " PD-L1"

showing 3 items of 13 documents

Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC…

2020

Introduction: Immune checkpoint inhibitors have provided substantial benefit in non-small cell lung cancer (NSCLC) with unprecedented results in terms of survival. However, the identification of reliable predictive biomarkers to these agents is lacking and multiple clinicopathological factors have been evaluated. The aim of this study was to analyze the potential role of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lactate dehydrogenase (LDH) levels in patients with pretreated NSCLC receiving nivolumab. Methods: This was a retrospective multicenter study involving 14 Italian centers, evaluating the role of some laboratory results in patients with NSCLC treat…

OncologyMale030213 general clinical medicineLung NeoplasmsNeutrophilsLymphocytenon-small cell lung cancer (NSCLC)DiseaseNSCLCchemistry.chemical_compoundLeukocyte Count0302 clinical medicineAntineoplastic Agents ImmunologicalCarcinoma Non-Small-Cell LungPD-180 and overLeukocytesPharmacology (medical)LymphocytesNon-Small-Cell LungAged 80 and overbiologyGeneral MedicineMiddle AgedPrognosisImmunologicalmedicine.anatomical_structureNivolumab030220 oncology & carcinogenesisLDH; Nivolumab; NLR; NSCLC; PD-1; PD-L1; PLR; Prognosis; Adult; Aged; Aged 80 and over; Antineoplastic Agents Immunological; Biomarkers; Carcinoma Non-Small-Cell Lung; Female; Humans; Leukocyte Count; Leukocytes; Lung Neoplasms; Lymphocytes; Male; Middle Aged; Neutrophils; Nivolumab; Prognosis; Retrospective StudiesFemaleNivolumabAdultPD-L1medicine.medical_specialtyLDHAntineoplastic AgentsPLRNONLR03 medical and health sciencesPD-L1Lactate dehydrogenaseInternal medicinemedicineHumansNeutrophil to lymphocyte ratioAgedRetrospective Studiesbusiness.industryCarcinomamedicine.diseaseRheumatologychemistrybiology.proteinLDH; Nivolumab; NLR; NSCLC; PD-1; PD-L1; PLR; PrognosisbusinessBiomarkers
researchProduct

Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer?

2014

Abstract: Immunotherapy has been studied for many years in lung cancer without significant results, making the majority of oncologists quite skeptical about its possible application for non-small cell lung cancer treatment. However, the recent knowledge about immune escape and subsequent cancer immunoediting has yielded the development of new strategies of cancer immunotherapy, heralding a new era of lung cancer treatment. Cancer vaccines, including both whole-cell and peptide vaccines have been tested both in early and advanced stages of non-small cell lung cancer. New immunomodulatory agents, including anti-CTLA4, anti-PD1/PDL1 monoclonal antibodies, have been investigated as monotherapy …

OncologyPD-L1medicine.medical_specialtyLung NeoplasmsSettore MED/06 - Oncologia Medicamedicine.medical_treatmentRacotumomabIpilimumabCIMAvaxtecemotideCancer VaccinesracotumomabCancer immunotherapyCarcinoma Non-Small-Cell LungInternal medicinePD-1medicineHumansbelagenpumatucel-LPharmacology (medical)ipilimumabLung cancerGVAXnon-small cell lung cancerNeoplasm StagingClinical Trials as TopicMAGE-A3CIMAvax; GVAX; MAGE-A3; PD-1; PD-L1; TG4010; belagenpumatucel-L; immunotherapy; ipilimumab; non-small cell lung cancer; racotumomab; tecemotide; vaccinesbusiness.industryAntibodies MonoclonalCancerImmunotherapyvaccinesmedicine.diseaseGVAXOncologyImmunologyTecemotideTG4010Human medicineimmunotherapybusinessmedicine.drug
researchProduct

COLON CANCER CELL-DERIVED EXOSOMES INDUCE MACROPHAGES TO ACQUIRE AN IMMUNOSUPPRESSIVE PHENOTYPE BY UPREGULATING PD-L1 EXPRESSION

Tumor-associated macrophages (TAMs) are a prominent component of cancer microenvironment having a key role in promoting tumor progression. Several studies have demonstrated that TAMs phenotypically and functionally correspond to M2-polarized macrophages thus they exert immunosuppressive functions also associated to the expression of programmed cell death ligand 1 (PD-L1). Within the local tumor microenvironment, tumor-derived exosomes (TDEs) are well known to play a key role in modulating the properties and the behavior of surrounding cells such as TAMs. Even if several studies demonstrated the ability of TDEs to induce M2-like macrophage polarization, few data are available about their inv…

Tumor derived exosomes TAMs PD-L1Settore BIO/13 - Biologia Applicata
researchProduct